Clinical trials: Adenocarcinoma of the Prostate
Prostate Adenocarcinoma, PSA Failure
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan.
- Conditions
- Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
- Trial name
- NCT02673151
- Testing
- Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Andrei Iagaru
Prostate Cancer
Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00311623
- Testing
- Rapamycin 3mg, Rapamycin 6mg, Radical prostatectomy
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
RATIONALE: Eating a diet high in vegetables may slow down disease progression in patients with prostate cancer. PURPOSE: This randomized clinical trial is studying how well diet works in altering disease progression in patients…
- Trial name
- NCT01238172
- Testing
- dietary education and counseling, prostate cancer foundation booklet
- Where
- 180 sites in United States
- Volunteers
- 478 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Prostate
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
The area around a tumor ("pre-metastatic niche") may be an area to which cancer cells are attracted. The study doctor will take blood and tumor samples to look for certain features linked with response to treatment so that they…
- Trial name
- NCT01832259
- Testing
- Pazopanib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
This phase II trial studies how well apalutamide works in treating patients with prostate cancer before radical prostatectomy. Androgen can cause the growth of prostate cancer cells.
- Trial name
- NCT03412396
- Testing
- Apalutamide, Quality-of-Life Assessment, Radical Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
This partially randomized phase II trial is studying how well giving bicalutamide together with RO4929097 works in treating patients with previously treated prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01200810
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, bicalutamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
This phase II trial studies how well gallium Ga 68-labeled gastrin-releasing peptide receptor (GRPR) antagonist BAY86-7548 (68Ga-RM2) positron emission tomography (PET)/computed tomography (CT) works in detecting regional nodal…
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- NCT03113617
- Testing
- Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Andrei Iagaru
Prostate Cancer
Docetaxel in Treating Patients With Relapsed Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00482274
- Testing
- docetaxel
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
This phase I/II trial is studying the side effects of giving cixutumumab together with temsirolimus and to see how well it works in treating patients with metastatic prostate cancer.
- Conditions
- Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01026623
- Testing
- Cixutumumab, Diagnostic Laboratory Biomarker Analysis, Temsirolimus
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
This phase II trial is studying how well fenretinide works in treating patients with biochemically (rising PSA level) recurrent hormone-naïve (no previous hormone therapy) prostate cancer.
- Trial name
- NCT00080899
- Testing
- fenretinide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Fulvestrant in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00217464
- Testing
- fulvestrant
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Roswell Park Cancer Institute
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
This pilot trial studies how well dexamethasone and re-treatment with enzalutamide work in treating patients with prostate cancer that has spread to other places in the body (metastatic), does not respond to hormone therapy…
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer
- Trial name
- DEXTER (NCT02491411)
- Testing
- Dexamethasone, Enzalutamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Adenocarcinoma of the Prostate
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer
- Trial name
- NCT00879619
- Testing
- sunitinib malate, docetaxel, prednisone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- John P. Fruehauf
Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
The purpose of this research study is to find out if a new anti-cancer drug, dasatinib (Sprycel®), previously approved for treatment of some forms of leukemia, will be safe and helpful in treating patients with hormone-refractory…
- Conditions
- Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer
- Trial name
- NCT00570700
- Testing
- Dasatinib
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of California, Irvine
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Prostate Cancer
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body.
- Trial name
- NCT01309672
- Testing
- abiraterone acetate, Prednisone
- Where
- 205 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer.
- Trial name
- NCT00024167
- Testing
- Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium
- Where
- 40 sites in United States
- Volunteers
- 265 people
- Sponsor
- M.D. Anderson Cancer Center
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma
Tivantinib in Treating Patients With Metastatic Prostate Cancer
This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer.
- Conditions
- Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01519414
- Testing
- Laboratory Biomarker Analysis, Tivantinib
- Where
- 20 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Prostate Adenocarcinoma
Evaluation of PSMA Antagonist Produced by Two Different Methods
Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers.
- Trial name
- NCT04685811
- Testing
- 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00567580
- Testing
- PBRT, PLNRT, AA
- Where
- 460 sites in United States, Canada and 2 more
- Volunteers
- 1,792 people
- Sponsor
- Radiation Therapy Oncology Group